

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ARDANA BIOSCIENCE LIMITED	12/23/2003
RECEIVING PARTY DATA	
Name:	MEDIOLANUM PHARMACEUTICALS LIMITED
Street Address:	7th Floor, Hume House
City:	Ballsbridge, Dublin 4
State/Country:	IRELAND
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	5635379
Patent Number:	5646301
Patent Number:	5668254
Patent Number:	5872100
CORRESPONDENCE DATA	
Fax Number:	(202)371-5950
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	eanderson@winston.com
Correspondent Name:	WINSTON & STRAWN LLP
Address Line 1:	1400 L Street, N.W.
Address Line 2:	Patent Department
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005-3502
NAME OF SUBMITTER:	Jeffrey A. Wolfson
Total Attachments: 4 source=87264-52 - Assignment#page1.tif source=87264-52 - Assignment#page2.tif source=87264-52 - Assignment#page3.tif source=87264-52 - Assignment#page4.tif	

CH \$160.00 5635379

PATENT

50005301

REEL: 015027 FRAME: 0170

FORMAL ASSIGNMENT

by

ARDANA BIOSCIENCE LIMITED, a company incorporated under the Companies Acts (Registered No. 4008598) and having its principal place of business at 58 Queen Street, Edinburgh, EH2 3NS ("Ardana");

in favour of itself and

MEDIOLANUM PHARMACEUTICALS LIMITED, a company incorporated under the laws of Ireland (Registered No. 362130) and having its principal place of business at 7th floor, Hume House, Ballsbridge, Dublin 4, Ireland ("MP").

WHEREAS:

- (A) Ardana is the lawful proprietor of the Patents and is willing to transfer the Patents to itself and to MP to hold as joint owners in equal *pro indiviso* shares, on the terms and conditions set out in this Assignment; and
- (B) MP is willing to become a joint owner of the Patents on the terms and conditions set out in this Assignment;

THE PARTIES AGREE as follows:-

1. DEFINITIONS

- 1.1 In this Assignment (including the Recitals), unless the context otherwise requires:-

Patents means the patents listed in the Schedule and any reissues, extensions, substitutions, continuations, divisions, continuation-in-part applications and supplementary protection certificates in any part of the world which are based on the patents listed in the Schedule; and

Schedule the Schedule annexed to and forming part of this Assignment.

2. **ASSIGNMENT**


2.1 Ardana hereby assigns to itself and to MP to hold as joint owners, in equal *pro indiviso* shares and MP and Ardana hereby accept the assignment of and agree to hold as joint owners in equal *pro indiviso* shares, all Ardana's property, right, title and interest in and to the Patents, including all statutory and common law rights.


3. **APPLICABLE LAW**

3.1 This Assignment will be governed by and construed and interpreted in accordance with the Laws of England and the parties hereby submit to the jurisdiction of the English Courts:

IN WITNESS WHEREOF these presents, printed on this and the one (1) preceding page together with the Schedule, are executed as follows:-

SIGNED by Dr. Maureen Lindsay for and on behalf of **ARDANA BIOSCIENCE LIMITED** at Edinburgh, Scotland on 23rd December 2003 in the presence of this witness:

Witness.....
Full Name..... AUSTIN DUNN
Address..... 191 WEST GEORGE STREET, GLASGOW



.....
Dr. Maureen Lindsay

SIGNED by Bruno Sacchi and Mrs Suzanne Boland, Directors and Authorised Signatories for and on behalf of **MEDIOLANUM PHARMACEUTICALS LIMITED** at Dublin, Ireland:

on 18 DECEMBER 2003.


.....

Bruno Sacchi


.....

Mrs Suzanne Boland


The Patent Schedule referred to in the foregoing Formal Assignment between Andana Bioscience Limited and Medicarium Pharmaceuticals Limited

The Patents

Title	Application Date	Application Number	Designated States	Granting Date	Publication/ Patent Number	Inventor
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	76997/91	AUSTRALIA	18.07.95	657475	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	2081450	CANADA	27.03.01	2081450	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	507922/91	JAPAN	21.06.02	3319595	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	92-702659	SOUTH KOREA	28.05.99	216386	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	98105280-1	HONG KONG	12.02.99	1006173	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	9591556.7	SINGAPORE	15.12.95	9591556.7	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	AUSTRIA	23.11.94	E114321	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	BELGIUM	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	DENMARK	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	FRANCE	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	GERMANY	23.11.94	69105270	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	GREECE	23.11.94	950400366	R. Deghenghi

ALL PATENT 3 83

Title	Application Date	Application Number	Designated States	Granting Date	Publication/ Patent Number	Inventor
Alkyltryptophan						
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	SPAIN	23.11.94	2067256	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	ITALY	23.11.94	20831 BE/95	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	LUXEMBOURG	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	THE NETHERLANDS	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	UNITED KINGDOM	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	SWEDEN	23.11.94	0531461	R. Deghenghi
Biologically Active Peptides containing D-2-Alkyltryptophan	17.04.91	91920995.7	SWITZERLAND/LIECHTENSTEIN	23.11.94	0531461	R. Deghenghi
D-2-Alkyltryptophan and peptides containing same	30.10.95	08/550046	US	03.06.97	5635379	R. Deghenghi
D-2-Alkyltryptophan compounds	04.04.96	08/627282	US	08.07.97	5646301	R. Deghenghi
D-2-Alkyltryptophan and peptides containing same	10.02.93	08/016862	US	16.09.97	5668254	R. Deghenghi
Peptides containing D-2-Alkyltryptophan	09.06.97	08/871418	US	16.02.99	5872100	R. Deghenghi

 ML
 PATENT 4 82